Valuation : Cerenis Therapeutics

Market Cap 80.44M 93.48M 75.69M 69.14M 129M 8.83B 130M 894M 347M 4.53B 351M 343M 14.59B P/E 2026 *
-4.18x
P/E 2027 * -6.76x
Enterprise Value 76.74M 89.18M 72.2M 65.96M 123M 8.42B 124M 853M 331M 4.32B 335M 328M 13.92B EV / Sales 2026 *
16.5x
EV / Sales 2027 * 5.42x
Free-Float
85.31%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 49 06/09/2019
Director of Finance/CFO - -
Chief Operating Officer - 01/01/2006
Director TitleAgeSince
Director/Board Member 49 06/09/2019
Director/Board Member 52 20/07/2010
Director/Board Member 76 06/02/2015
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 93.48M
-1.79%-2.27%+43.23%+88.96% 67.98B
-2.06%-0.18%+39.67%+86.44% 64.94B
-0.31%+6.54%-12.96%+378.92% 27.58B
+0.86%+1.65%-7.74%-14.95% 26.06B
-3.00%-2.90%+33.13%+12.54% 25.74B
-1.46%+0.42%+23.61%-18.61% 20.09B
-2.96%-15.21%+216.20%+368.10% 17.16B
-1.49%-4.88%-6.60%+531.89% 14.92B
-0.20%+8.37%+55.78%+164.98% 14.62B
Average -1.24%+0.26%+42.70%+177.58% 31.01B
Weighted average by Cap. -1.52%+0.18%+38.37%+137.35%

Financials

2026 *2027 *
Net sales 4.66M 5.42M 4.38M 4M 7.49M 511M 7.51M 51.81M 20.1M 262M 20.33M 19.89M 845M 14.77M 17.16M 13.89M 12.69M 23.74M 1.62B 23.81M 164M 63.71M 831M 64.44M 63.04M 2.68B
Net income -19.83M -23.04M -18.65M -17.04M -31.88M -2.18B -31.96M -220M -85.54M -1.12B -86.52M -84.63M -3.6B -12.92M -15.02M -12.16M -11.11M -20.78M -1.42B -20.83M -144M -55.75M -727M -56.39M -55.16M -2.34B
Net Debt -3.7M -4.3M -3.48M -3.18M -5.95M -406M -5.97M -41.14M -15.96M -208M -16.15M -15.79M -671M -400K -465K -376K -344K -643K -43.89M -645K -4.45M -1.73M -22.52M -1.75M -1.71M -72.54M
Logo Cerenis Therapeutics
ABIONYX Pharma SA is specialized in research & development into HDL therapies (High Density lipoproteins) intended for the treatment of cardiovascular and metabolic disorders. HDLs, also known as good cholesterol, are fat and protein complexes that contribute to the transportation of cholesterol from the body's tissues to the liver and are linked to a decrease in the risk of atherosclerosis and coronary diseases. At the end of 2025, the company boasted a portfolio of 3 products in clinical development.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.900EUR
Average target price
10.50EUR
Spread / Average Target
+452.63%

Annual profits - Rate of surprise